The journal of nutrition, health & aging

, Volume 15, Issue 1, pp 65–70 | Cite as

A practical approach to lipid management in the elderly

Article

Abstract

Cardiovascular disease (CVD) increases in a curvilinear fashion after 65 years in men and 75 years in women and the majority of all cardiovascular events occur in individuals older then 65 years. There are notable differences in the clinical assessment of hyperlipidaemia, cardiovascular risk estimation as well as the safety and tolerability profiles in the elderly compared to younger individuals. Clinical trial data have now demonstrated the benefits of statin treatment in the elderly in both the primary and secondary prevention settings. There is however limited data for individuals older than 80 years. Little data is available on other lipid modifying medication in the elderly. With continuing increases in average life expectancy, preventive efforts will become increasingly important for preventing morbidity, improving quality of life, and reducing healthcare expenditures for older persons. This emphasizes the importance of clinical decisionmaking and weighing up the risks and benefits of treatment.

Key words

Lipid management elderly cardiovascular disease 

Non-standard abbreviations

CVD

cardiovascular disease

LDL-C

low density lipoprotein cholesterol

HDL

high density lipoprotein

TG

triglycerides

TC

total cholesterol

CYP

cytochrome P450

ALT

alanine amino transferase

AST

aspartate amino transferase

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    World Health Organization. Top 10 causes of death [Fact sheet N°310]; updated October 2008 [cited January 2010] Available from: http://www.who.int/mediacentre/factsheets/fs310/en/index.html
  2. 2.
    Rothwell P, Coull A, Silver L, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366:1773–1783CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294:1255–1259CrossRefPubMedGoogle Scholar
  4. 4.
    Fries JF. Frailty, heart disease, and stroke: the Compression of Morbidity Paradigm. Am J Prev Med. 2005;29:164–168CrossRefPubMedGoogle Scholar
  5. 5.
    Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50PubMedGoogle Scholar
  6. 6.
    Anum EA, Adera T. Hypercholesterolemia and coronary heart disease in the elderly: a meta-analysis. Ann Epidemiol. 2004;14:705–721.CrossRefPubMedGoogle Scholar
  7. 7.
    Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet. 2007; 370:1829–1839CrossRefGoogle Scholar
  8. 8.
    Corti MC, Guralnik JM, Salive ME et al. Clarifying the direct relationship between total cholesterol and death from coronary heart disease in older persons. Ann Inter Med 1997;126:753–760Google Scholar
  9. 9.
    Warnick GR, Nauck M, Rifai N. Evolution of Methods for Measurement of HDLCholesterol: From Ultracentrifugation to Homogeneous Assays. Clin Chem 2001;47:1579–1596PubMedGoogle Scholar
  10. 10.
    Vaisar T Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746–756CrossRefPubMedGoogle Scholar
  11. 11.
    Karlsson H, Leanderson P, Tagesson C et al. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two dimensional gel electrophoresis and mass spectrometry. Proteomics 2005;5:551–565CrossRefPubMedGoogle Scholar
  12. 12.
    Contois JH, McConnell JP, Sethi AA, et al; AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55:407–419CrossRefPubMedGoogle Scholar
  13. 13.
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502PubMedGoogle Scholar
  14. 14.
    Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz ID Jr. Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem 1992;38:150–160PubMedGoogle Scholar
  15. 15.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143–3421Google Scholar
  16. 16.
    British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91Suppl 5:v1–52Google Scholar
  17. 17.
    Ehrenstein MR, Jury EC, Mauri C. Statin for Atherosclerosis — As good as it gets? N Eng J Med 2005;352:1:73–75CrossRefGoogle Scholar
  18. 18.
    Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278CrossRefGoogle Scholar
  19. 19.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389Google Scholar
  20. 20.
    Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009CrossRefPubMedGoogle Scholar
  21. 21.
    The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357CrossRefGoogle Scholar
  22. 22.
    Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211–4218PubMedGoogle Scholar
  23. 23.
    Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID Trial. Ann Intern Med. 2001;134:931–940PubMedGoogle Scholar
  24. 24.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22CrossRefGoogle Scholar
  25. 25.
    Shepherd J, Blauw G, Murphy M, et al, on behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–1630CrossRefPubMedGoogle Scholar
  26. 26.
    Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R. Is it time for a primary prevention trial in the elderly? Stroke 2007;38:441–450CrossRefPubMedGoogle Scholar
  27. 27.
    Abramson J, Wright JM. Are clinical guidelines evidence based? Lancet 2007;369:168–169CrossRefPubMedGoogle Scholar
  28. 28.
    Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. N Engl J Med 2008;359:2195–2207CrossRefPubMedGoogle Scholar
  29. 29.
    Viljoen A, Wierzbicki AS. Enhanced LDL-C reduction: lower is better. Does it matter how? Int J Clin Pract. 2008;62(4):518–520.CrossRefPubMedGoogle Scholar
  30. 30.
    Wierzbicki AS. Muddy waters: more stormy SEAS for ezetimibe. Int J Clin Pract. 2008;62:1470–1473CrossRefPubMedGoogle Scholar
  31. 31.
    Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004;292:2622–2631.CrossRefPubMedGoogle Scholar
  32. 32.
    Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781–1790CrossRefPubMedGoogle Scholar
  33. 33.
    Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52–60CrossRefGoogle Scholar
  34. 34.
    Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24–33CrossRefPubMedGoogle Scholar
  35. 35.
    Maddrey WC. Drug-induced hepatotoxicity. J Clin Gastroenterol 2005;39:83–89.CrossRefGoogle Scholar
  36. 36.
    Williams MA, Fleg JL, Ades PA, et al; American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Secondary prevention of coronary heart disease in the elderly (with an emphasis on patients ≥ 75 years of age): An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105:1735–1743CrossRefPubMedGoogle Scholar
  37. 37.
    Thienpont LM, Van Uytfanghe K, De Leenheer AP. Reference measurement systems in clinical chemistry. Clin Chim Acta 2002;323:73–87CrossRefPubMedGoogle Scholar
  38. 38.
    McBride PE. Triglycerides and Risk for Coronary Heart Disease. JAMA 2007;298:336–338CrossRefPubMedGoogle Scholar
  39. 39.
    Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab 2007;92:1581–1589CrossRefPubMedGoogle Scholar
  40. 40.
    Mao EQ, Tang YQ, Zhang SD. Formalized therapeutic guideline for hyperlipidemic severe acute pancreatitis. World J Gastroenterol 2003;9:2622–2626PubMedGoogle Scholar
  41. 41.
    Reilly MP, Tall AR. HDL proteomics: pot of gold or Pandora’s box? J Clin Invest. 2007;117:595–598CrossRefPubMedGoogle Scholar
  42. 42.
    Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk of coronary events. N Eng JMed 2007;357:2109–2122CrossRefGoogle Scholar
  43. 43.
    Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006;60:442–449CrossRefPubMedGoogle Scholar
  44. 44.
    Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003;19:155–168CrossRefPubMedGoogle Scholar
  45. 45.
    Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 2004;58:706–713CrossRefPubMedGoogle Scholar
  46. 46.
    The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381CrossRefGoogle Scholar
  47. 47.
    Kamal-Bahl S, Burke T, Watson D, Wentworth C, Ma L. Dosage and titration patterns of extended release niacin in clinical practice. Circulation 2006; 113:e814. American Heart Association 7th Scientific Forum of Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington DC, 2006CrossRefGoogle Scholar
  48. 48.
    Viljoen A. Resurrecting an old drug — a flash in the pan or here to stay? Int J Clin Pract 2009;63:3–6CrossRefPubMedGoogle Scholar
  49. 49.
    Viljoen A. Cardiovascular risk estimation — making sense of the numbers. Int J Clin Pract. 2008;62:1300–1303CrossRefPubMedGoogle Scholar
  50. 50.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307.CrossRefPubMedGoogle Scholar
  51. 51.
    Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–696CrossRefPubMedGoogle Scholar
  52. 52.
    Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 Apr 30;360(18):1851–1861.CrossRefPubMedGoogle Scholar
  53. 53.
    Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009 Jun 30;338:b2376.CrossRefPubMedGoogle Scholar

Copyright information

© Serdi and Springer Verlag France 2011

Authors and Affiliations

  1. 1.Department of Chemical PathologyLister HospitalStevenageUK
  2. 2.Bedfordshire and Hertfordshire Postgraduate Medical SchoolPutteridge Bury CampusLutonUK

Personalised recommendations